Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 17/20 | 0.60 |
| ▸ | MMP1 | P03956 | 2/20 | 0.60 |
| ▸ | MMP9 | P14780 | 16/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MMP8 | P22894 | 10/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MMP14 | P50281 | 13/20 | 0.48 |
| ▸ | MMP3 | P08254 | 3/20 | 0.48 |
| ▸ | MMP7 | P09237 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10238686 | 0.88 | MMP9 (0.71) | MMP2MMP1MMP9ALDH1A1POLB | |
| SCHEMBL10187462 | 0.84 | MMP2 (0.67) | MMP2MMP1MMP9ALDH1A1MMP8 | |
| SCHEMBL313439 | 0.82 | MMP2 (0.71) | MMP2MMP1MMP9ALDH1A1POLB | |
| SCHEMBL12717274 | 0.82 | MMP9 (0.78) | MMP2MMP1MMP9MMP8MMP14 | |
| SCHEMBL12717348 | 0.81 | MMP2 (0.69) | MMP2MMP1MMP9ALDH1A1SMN1; SMN2 | |
| SCHEMBL17026726 | 0.80 | MMP2 (0.58) | MMP2MMP1MMP9MMP8MMP14 | |
| SCHEMBL4292169 | 0.79 | MMP2 (0.67) | MMP2MMP1MMP9ALDH1A1MMP8 | |
| SCHEMBL14727900 | 0.77 | MMP2 (0.64) | MMP2MMP1MMP9ALDH1A1MMP8 | |
| SCHEMBL17039173 | 0.77 | MMP2 (0.55) | MMP2MMP1MMP9MMP8MMP14 | |
| SCHEMBL314080 | 0.75 | MMP2 (1.00) | MMP2MMP1MMP9MMP8LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093287-B2 | Inhibitors of matrix metalloproteinases | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110224275-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES | NOTRE DAME UNIVERSITY (US) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224275-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES | MMP9, MMP1, MMP2 | MMP2 3/4885MMP1 2/4885MMP9 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.